What Happened
- Data analysis reveals the significant financial relief that customs duty cuts on cancer drugs — announced across Union Budgets 2025 and 2026 — are delivering to patients in both public and private hospitals.
- Budget 2025-26 exempted 36 life-saving drugs (including cancer drugs like Tepotinib, Avelumab, and Asciminib) from Basic Customs Duty (BCD) and extended full exemption to medicines provided under Patient Assistance Programs.
- Budget 2026 went further, cutting customs duty on 17 additional cancer drugs, deepening the relief for patients accessing targeted and immunotherapy-based treatments.
- While private hospitals charge higher absolute amounts for cancer treatment, the relative financial burden (as a share of household income) is disproportionately higher for patients in the government sector, who tend to be from lower-income groups.
- India's out-of-pocket expenditure (OOPE) on cancer is catastrophic for most households: the odds of impoverishment due to cancer treatment costs are six times higher than those due to infectious diseases.
Static Topic Bridges
Customs Duty on Pharmaceuticals — Structure and Policy Rationale
Basic Customs Duty (BCD) is levied on imported goods under the Customs Act, 1962, at rates specified in the First Schedule to the Customs Tariff Act, 1975. The Union Budget, presented by the Finance Minister, can modify BCD rates for specific products. Life-saving drugs — particularly imported oncology drugs for which no domestic equivalent exists — are routinely targeted for duty reductions or exemptions to make them accessible. The logic is simple: high customs duty on medicines that are not manufactured domestically raises their retail price with no benefit to domestic industry, directly harming patients.
- Customs Act, 1962: primary legislation governing import duties
- Customs Tariff Act, 1975 (First Schedule): base duty rates; amended by annual Finance Bills
- BCD on pharmaceutical products (standard): 10% (for most formulations)
- Exemption mechanism: government can issue Customs Notification under Section 25 of Customs Act, 1962
- Budget 2025-26 exemptions: 36 life-saving drugs from BCD; 6 additional drugs reduced to 5% BCD
- Budget 2026: 17 more cancer drugs exempted from customs duty
- Patient Assistance Programs (PAPs): pharma companies supply high-cost drugs free/subsidised to eligible patients; 37 more PAP medicines got BCD exemption in Budget 2025-26
Connection to this news: Each percentage point of customs duty directly feeds into the import price of an oncology drug, which is then marked up through the supply chain; duty exemptions can reduce retail prices by 10–40% depending on the drug's import cost composition.
Financial Toxicity of Cancer Treatment in India
"Financial toxicity" is the term used to describe the negative economic impact of cancer treatment on patients and their families, including depletion of savings, distress borrowing, and sale of assets to meet treatment costs. India's public health expenditure is approximately 1.5% of GDP — well below the WHO recommendation of 5% — leaving healthcare largely financed by out-of-pocket payments. For cancer, which requires multi-modal treatment (surgery, chemotherapy, radiation, immunotherapy, targeted therapy), costs are extremely high, sustained over months or years, and largely unavoidable.
- India's public health expenditure: ~1.5% of GDP (among the lowest globally)
- OOPE (Out-of-Pocket Expenditure) share of total health spending: ~50–60% in India
- Average cancer OOP expenditure: ₹35,817 (males) / ₹20,496 (females) — from research studies
- Monthly inpatient cancer OOPE: ₹6,549 (= 37% of average monthly household consumption)
- Odds of impoverishment due to cancer treatment OOPE: 6× higher than for infectious diseases
- Catastrophic health expenditure: when OOPE exceeds 10% of household consumption
- Cancer incidence in India: ~14 lakh (1.4 million) new cases annually; leading cause of non-communicable disease mortality
Connection to this news: The duty cuts specifically target high-cost imported oncology drugs — targeted therapies and immunotherapies — which are disproportionately responsible for financial toxicity because they cost ₹50,000–₹2,00,000+ per treatment cycle and have no affordable domestic substitute.
National Cancer Control Programme and Institutional Framework
India's approach to cancer is governed through a combination of the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), which subsumes cancer, diabetes, and cardiovascular diseases, and specific cancer care initiatives. Budget 2025-26 also announced establishment of 200 daycare cancer centres in district hospitals, intended to reduce the need for patients in Tier-2 and Tier-3 cities to travel to metro hospitals for chemotherapy and immunotherapy — a significant contributor to indirect cost burden.
- National Programme for NCD Prevention and Control (NP-NCD): covers cancer, diabetes, CVD, stroke
- National Cancer Registry Programme (NCRP): population-based data; under Indian Council of Medical Research (ICMR)
- Rashtriya Arogya Nidhi (RAN): financial assistance for below-poverty-line patients with life-threatening diseases including cancer
- Pradhan Mantri Jan Arogya Yojana (PM-JAY): covers hospitalisation costs up to ₹5 lakh/family/year; covers cancer surgeries and chemotherapy under defined packages
- Budget 2025-26: 200 daycare cancer centres announced for district hospitals
- AIIMS network expansion: more AIIMS functioning across states improves cancer care access
Connection to this news: Duty cuts on cancer drugs work alongside PM-JAY and RAN to reduce financial burden — but their impact is maximised only when combined with robust insurance coverage, since duty cuts lower drug prices but do not directly subsidise patients without insurance who purchase drugs out-of-pocket.
Key Facts & Data
- Budget 2025-26: 36 life-saving drugs (including cancer drugs) exempted from BCD; 37 PAP medicines also exempted
- Budget 2026: 17 additional cancer drugs exempted from customs duty
- Customs duty on pharmaceuticals (standard): 10% BCD
- Legal basis for exemptions: Section 25, Customs Act, 1962
- India's public health expenditure: ~1.5% of GDP
- OOPE as share of health spending: ~50–60%
- Average cancer OOPE (per patient): ₹35,817 (males), ₹20,496 (females)
- Cancer treatment impoverishment risk: 6× higher than infectious diseases
- Cancer incidence in India: ~14 lakh new cases/year
- PM-JAY cover: up to ₹5 lakh per family per year (covers cancer hospitalisation)
- 200 daycare cancer centres to be set up in district hospitals (Budget 2025-26)
- ICMR: nodal agency for cancer research and the National Cancer Registry Programme